Spring Fertility (“Spring”), a leading provider of fertility care in Northern California, today announced it has received a significant growth equity investment from Wildcat Capital Management, a New York based family office. Since opening in 2016, Spring has quickly become the premier fertility center in Northern California and one of the fastest growing fertility centers in the country by achieving consistently superior clinical results with high patient satisfaction scores. Spring anticipates using this investment to fuel further scientific innovation and expand access to its care platform in the Bay Area and across North America. Spring currently serves patients from offices in San Francisco, East Bay and Silicon Valley. Advanced procedures are performed in an innovative, state of the art lab which deploys unique, customized technology that more accurately replicates the body’s internal environment in the lab.
“We are proud to partner with Spring as it advances the science of fertility and delivers the highest-quality care possible. Spring’s focus on innovation and their relentless pursuit of improved clinical, lab, and experiential standards uniquely position it as a leader in the fertility sector.”
Spring was founded by Drs. Peter Klatsky and Nam Tran, as they sought to change the experience and outcomes for patients seeking fertility care. Drs. Klatsky and Tran will retain majority ownership post-transaction.
“Wildcat is excited to support the Spring team as they continue to re-invent the patient experience while providing exceptional clinical outcomes,” said Drew Tarlow, Principal at Wildcat Capital Management. “We are proud to partner with Spring as it advances the science of fertility and delivers the highest-quality care possible. Spring’s focus on innovation and their relentless pursuit of improved clinical, lab, and experiential standards uniquely position it as a leader in the fertility sector.”
“After years of directing research at the best academic centers in the country, it’s rewarding to see those innovations quickly translate into patient care,” explains Spring’s Scientific Director Nam Tran, MD, PhD. “We have been able to accomplish several ‘firsts’ in our lab and are excited to use this investment to further develop our scientific research program and continue to innovate novel therapeutic options to help our patients. Our unique egg to embryo environmental controls have reduced attrition by over 25% from fertilization through embryo development. This means a significantly higher chance of success with fewer disappointing outcomes.”
“We exist to help our patients pursue and achieve their goals. Our desire to innovate while improving access and quality aligns with Wildcat’s patient, long-term approach,” said Dr. Peter Klatsky of Spring Fertility. “With Wildcat’s investment, Spring will have the resources to continue expanding access while investing in our clinical and technological capabilities to create a differentiated and superior experience for our patients, employees, and physicians.”
Bass Berry Sims advised Spring Fertility on the transaction, and McDermott Will & Emery, Alvarez & Marsal, Aon, and Avalere advised Wildcat Capital Management.
About Spring Fertility
Spring Fertility was founded by leading physicians with the goal of redefining the reproductive and fertility patient experience to improve comfort, communication and care while advancing scientific excellence. It quickly became the premier fertility platform in Northern California, and one of the country’s fastest growing. The Company was founded in 2016 by Peter Klatsky, MD, MPH and Nam Tran, MD, PhD and provides a broad range of fertility treatments including IVF and egg freezing. Spring’s state-of-the-art fertility lab is located in San Francisco and the company operates patient centers in Oakland and Redwood City.
Source: Spring Fertility